Merkel Cell Carcinoma: Complete Clinical Remission Associated With Disease Progression
A. Bertolotti(Inserm), Thomas Jouary(Hôpital Saint-André), Pierre Mélard, Alain Taı̈eb(Université de Bordeaux), B. Vergier(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Khaled Ezzedine(Hôpitaux Universitaires Henri-Mondor), H. Conte, Louis François
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k